LB Pharmaceuticals (LBRX) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for LB Pharmaceuticals (LBRX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||
Research And Development | 15M (+34.40%) | 11M (+350.41%) | 2.42M | - | 3.42M (-91.56%) | 41M (+280.02%) | 11M | - | - |
Selling General And Administrative | 7.46M (-4.73%) | 7.83M (+176.68%) | 2.83M | - | 3.01M (-63.47%) | 8.24M (+52.03%) | 5.42M | - | - |
Operating Expenses | 22M (+17.99%) | 19M (+256.76%) | 5.25M | - | 6.43M (-86.81%) | 49M (+203.17%) | 16M | - | - |
Depreciation And Amortization | 80K (-66.67%) | 240K | - | - | 80K (-11.11%) | 90K | - | - | - |
Operating Income | |||||||||
Ebit | -19.05M (+66.09%) | -11.47M (+222.19%) | -3.56M (-26.90%) | -4.87M (-8.29%) | -5.31M (+4.73%) | -5.07M (-64.25%) | -14.18M (-48.68%) | -27.63M (+70.35%) | -16.22M |
EBITDA | -18.97M (+68.92%) | -11.23M (+215.45%) | -3.56M (-26.90%) | -4.87M (-6.88%) | -5.23M (+5.02%) | -4.98M (-64.88%) | -14.18M (-48.68%) | -27.63M (+70.35%) | -16.22M |
Other Income / Expenses | |||||||||
Interest Income | 2.85M (-4.36%) | 2.98M (+319.72%) | 710K | - | 240K (-82.09%) | 1.34M (+252.63%) | 380K | - | - |
Net Interest Income | 2.85M (-4.36%) | 2.98M (+319.72%) | 710K | - | 240K (-82.09%) | 1.34M (+252.63%) | 380K | - | - |
Other Non Operating Income | 3.05M (-41.35%) | 5.20M (+207.69%) | 1.69M | - | 1.12M (-35.26%) | 1.73M (-8.95%) | 1.90M | - | - |
Net Income | |||||||||
Income Before Tax | -19.05M (+16.59%) | -16.34M (+358.99%) | -3.56M | - | -5.31M (-89.15%) | -48.92M (+244.99%) | -14.18M | - | - |
Net Income From Continuing Operations | -19.05M (+66.09%) | -11.47M (+222.19%) | -3.56M (-26.90%) | -4.87M (-8.29%) | -5.31M (+4.73%) | -5.07M (-64.25%) | -14.18M (-48.68%) | -27.63M (+70.35%) | -16.22M |
Net Income | -19.05M (+66.09%) | -11.47M (+222.19%) | -3.56M (-26.90%) | -4.87M (-8.29%) | -5.31M (+4.73%) | -5.07M (-64.25%) | -14.18M (-48.68%) | -27.63M (+70.35%) | -16.22M |
Comprehensive Income Net Of Tax | -19.01M (-24.41%) | -25.15M (+596.68%) | -3.61M | - | -5.42M (-91.43%) | -63.26M (+336.28%) | -14.50M | - | - |